Sales up 23% for Korean CDMO powerhouse Samsung Biologics
After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, including…
Samsung Biologics’ production streak continues with $518M US pharma contract
Samsung Biologics, which has enjoyed a booming contract drug manufacturing streak over the past year, has inked another …
Samsung Bio inks US contract manufacturing deal worth $1.3B
Despite persistent uncertainty under the Trump administration’s international trade policy, Korea’s Samsung Biologics continues to snare billion-dollar contract…
SK pharmteco to Attend CPHI, Showcasing Multimodal CDMO Capabilities and Global Manufacturing Infrastructure
Executive leadership and technical experts to highlight end-to-end small molecule and viral vectors solutions SK pharmteco is Official…
Samsung Biologics’ labor union holds general strike
Unionized workers at fast-growing South Korean CDMO Samsung Biologics kicked off a planned general strike on Friday, escalating…
Thousands-wide union strike continues at CDMO Samsung Biologics
A union strike of thousands of workers is still ongoing at Korean CDMO Samsung Biologics, costing the company…
Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPaptide
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market…
Samsung Biologics Labor and Management End 100-Day Standoff, Accept Post-Adjustment to Seek Resolution Within the Year — BigGo Finance
Samsung Biologics (207940.KS) labor and management have agreed to end their wage and collective bargaining agreement standoff that…
Samsung Biologics Jumps 5% Premarket as Moderna Soars 177%
Samsung Biologics Samsung Biologics (207940.KS) surged nearly 6% in premarket trading after U.S. biotech firm Moderna reported significant…
SK pharmteco Marks Construction Progress with Ribbon
RANCHO CORDOVA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) — SK pharmteco recently hosted a formal ribbon-cutting ceremony to…
China’s WuXi AppTec Surpasses $4.3 Billion in First-Half Revenue, Overtaking Lonza to Target Global CDMO Crown — BigGo Finance
China’s contract development and manufacturing organization (CDMO) WuXi AppTec has shaken up the global CDMO market by surpassing…
Samsung Biologics Surges 11% as KOSPI Plunges on Strong Earnings
Samsung Biologics Plant 4. Samsung Biologics Samsung Biologics (207940.KS) extended gains of more than 11% on the 24th,…